Some are true believers in the power of sophisticated mRNA vaccines, some go for exotic viral vectors, and some are tied to the time-tested cocktail of attenuated viral particles. Whatever approach you prefer, it's clear there's likely more than one way to make a coronavirus vaccine.
At present, there's no guarantee that any given vaccine modality will perform better than another, nor is there any indication that one might be more profitable than the rest. Each vaccine technology entails a different set of risks and benefits, not to mention profound implications for the cost of manufacturing, and investors need to know how to plan their portfolios appropriately.
Image source: Getty Images.